Mechanisms of Opioid-Induced Tolerance and Hyperalgesia

Pain Management Nursing

Volumn 8, Issue 3, 2007, Pages 113-121

  DuPen, Anna ^a   Shen, Danny ^b   Ersek, Mary ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; CHOLECYSTOKININ RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR; RETINA S ANTIGEN;

ARTICLE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECT; DRUG TOLERANCE; HUMAN; HYPERALGESIA; NURSE ATTITUDE; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHYSIOLOGY;

ANALGESICS, OPIOID; ARRESTINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; GTP-BINDING PROTEINS; HUMANS; HYPERALGESIA; NURSE'S ROLE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PHARMACOGENETICS; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID;

EID: 34548094306     PISSN: 15249042     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmn.2007.02.004     Document Type: Article

References (94)

1. Angst M.S., and Clark J.D. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104 (2006) 570-587
2. Arden J.R., Segredo V., Wang Z., Lameh J., and Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. Journal of Neurochemistry 65 (1995) 1636-1645
3. Benitez del Rosario M.A., Feria M., Salinas-Martin A., Martinez-Castillo L.P., and Martin-Ortega J.J. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer 101 (2004) 2866-2873
4. Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M., Linnoila M., et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. Molecular Psychiatry 2 (1997) 490-494
5. Bernstein Z.P., Yucht S., Battista E., Lema M., and Spaulding M.B. Proglumide as a morphine adjunct in cancer pain management. Journal of Pain & Symptom Management 15 (1998) 314-320
6. Bohn L.M., Lefkowitz R.J., and Caron M.G. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. Journal of Neuroscience 22 (2002) 10494-10500
7. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., and Lin F.T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286 (1999) 2495-2498
8. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proceeding of the National Academies of Science of the United States of America 95 (1998) 9608-9613
9. Celerier E., Rivat C., Jun Y., Laulin J.P., Larcher A., Reynier P., et al. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology 92 (2000) 465-472
10. Chavkin C., and Goldstein A. Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea. Life Sciences 31 (1982) 1687-1690
11. Chavkin C., and Goldstein A. Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus. Proceeding of the National Academies of Science of the United States of America 81 (1984) 7253-7257
12. Chindalore V.L., Craven R.A., Yu K.P., Butera P.G., Burns L.H., and Friedmann N. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. Journal of Pain 6 (2005) 392-399
13. Clark J.L., and Kalan G.E. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. Journal of Pain & Symptom Management 10 (1995) 310-314
14. Collin E., Poulain P., Gauvain-Piquard A., Petit G., and Pichard-Leandri E. Is disease progression the major factor in morphine "tolerance" in cancer pain treatment?. Pain 55 (1993) 319-326
15. Compton M.A. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. Journal of Pain & Symptom Management 9 (1994) 462-473
16. Compton P., Charuvastra V.C., and Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug & Alcohol Dependence 63 (2001) 139-146
17. Crain S.M., and Shen K.F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84 (2000) 121-131
18. Davis A.M., and Inturrisi C.E. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. Journal of Pharmacol Exp Ther 289 (1999) 1048-1053
19. De Stoutz N.D., Bruera E., and Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. Journal of Pain Symptom & Management 10 (1995) 378-384
20. Dourish C.T., Hawley D., and Iversen S.D. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. European Journal of Pharmacology 147 (1988) 469-472
21. Doverty M., White J.M., Somogyi A.A., Bochner F., Ali R., and Ling W. Hyperalgesic responses in methadone maintenance patients. Pain 90 (2001) 91-96
22. Drake R., Longworth J., and Collins J.J. Opioid rotation in children with cancer. Journal of Palliative Medicine 7 (2004) 419-422
23. Duttaroy A., and Yoburn B.C. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 82 (1995) 1226-1236
24. Eilers H., Philip L.A., Bickler P.E., McKay W.R., and Schumacher M.A. The reversal of fentanyl-induced tolerance by administration of "small-dose" ketamine. Anesthesia & Analgesia 93 (2001) 213-214
25. Elliott K., Hynansky A., and Inturrisi C.E. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 59 (1994) 361-368
26. Estfan B., LeGrand S.B., Walsh D., Lagman R.L., and Davis M.P. Opioid rotation in cancer patients: pros and cons. Oncology (Williston Park) 19 (2005) 511-516
27. Ferguson S.S., Zhang J., Barak L.S., and Caron M.G. Role of beta-arrestins in the intracellular trafficking of G-protein-coupled receptors. Advances in Pharmacology 42 (1998) 420-424
28. Finn A.K., and Whistler J.L. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32 (2001) 829-839
29. Foley K. Changing concepts of tolerance to opioids: what the cancer patient has taught us. In: Chapman C.R., and Foley K.M. (Eds). Current and emerging issues in cancer pain: research and practice (1993), Raven Press, New York 331-350
30. Galer B.S., Lee D., Ma T., and Schlagheck T. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 115 (2005) 284-295 B., N.
31. Gardell L.R., King T., Ossipov M.H., Rice K.C., Lai J., Vanderah T.W., et al. Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neuroscience Letters 396 (2006) 44-49
32. Gardell L.R., Wang R., Burgess S.E., Ossipov M.H., Vanderah T.W., Malan Jr. T.P., et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. Journal of Neuroscience 22 (2002) 6747-6755
33. Gorman A.L., Elliott K.J., and Inturrisi C.E. The d- and l-isomers of methadone bind to the noncompetitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters 223 (1997) 5-8
34. Haley J.E., Sullivan A.F., and Dickenson A.H. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Research 518 (1990) 218-226
35. Hirota T., Ieiri I., Takane H., Sano H., Kawamoto K., Aono H., et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metabolism & Disposition 31 (2003) 677-680
36. Ho K.Y., Gan T.J., and Habib A.S. Gabapentin and postoperative pain-a systematic review of randomized controlled trials. Pain 126 (2006) 91-101
37. Indelicato R.A., and Portenoy R.K. Opioid rotation in the management of refractory cancer pain. Journal of Clinical Oncology 20 (2002) 348-352
38. Ivarsson M., and Neil A. Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross-tolerance. Pharmacology & Toxicology 65 (1989) 368-371
39. King T., Ossipov M.H., Vanderah T.W., Porreca F., and Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?. Neurosignals 14 (2005) 194-205
40. Kloke M., Rapp M., Bosse B., and Kloke O. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care in Cancer 8 (2000) 479-486
41. Lauretti G.R., Lima I.C., Reis M.P., Prado W.A., and Pereira N.L. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 90 (1999) 1528-1533
42. Li T., Zhu Z.H., Liu X., Hu X., Zhao J., Sham P.C., et al. Association analysis of polymorphisms in the DRD4 gene and heroin abuse in Chinese subjects. American Journal of Medical Genetics 96 (2000) 616-621
43. Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., and Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12 (2002) 3-9
44. Lotsch J., Zimmermann M., Darimont J., Marx C., Dudziak R., Skarke C., et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology 97 (2002) 814-819
45. Luttrell L.M., and Lefkowitz R.J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. Journal of Cell Science 115 (2002) 455-465
46. Lynch M.E. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Research & Management 10 (2005) 133-144
47. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends in Neuroscience 18 (1995) 22-29
48. Mansour A., Khachaturian H., Lewis M.E., Akil H., and Watson S.J. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. Journal of Neuroscience 7 (1987) 2445-2464
49. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100 (2002) 213-217
50. Mao J. Opioid-induced abnormal pain sensitivity. Current Pain & Headache Reports 10 (2006) 67-70
51. Mao J., Price D.D., and Mayer D.J. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. Journal of Neuroscience 14 (1994) 2301-2312
52. Mao J., Price D.D., and Mayer D.J. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61 (1995) 353-364
53. Mao J., Sung B., Ji R.R., and Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. Journal of Neuroscience 22 (2002) 8312-8323
54. McCleane G.J. Cholecystokinin antagonists a new way to improve the analgesia from old analgesics?. Current Pharmaceutical Design 10 (2004) 303-314
55. McCleane G.J. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain. Anesthesia & Analgesia 87 (1998) 1117-1120
56. McCleane G.J. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine. Clinical Journal of Pain 19 (2003) 200-201
57. McNicol E., Horowicz-Mehler N., Fisk R.A., Bennett K., Gialeli-Goudas M., Chew P.W., et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. Journal of Pain 4 (2003) 231-256
58. Mercadante S. Ketamine in cancer pain: an update. Palliative Medicine 10 (1996) 225-230
59. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86 (1999) 1856-1866
60. Morley J.S. Opioid rotation: does it have a role?. Palliative Medicine 12 (1998) 464-466
61. Moulin D.E., Ling G.S., and Pasternak G.W. Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain 33 (1988) 233-239
62. Noble F., and Cox B.M. Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment. British Journal of Pharmacology 117 (1996) 161-169
63. Ossipov M.H., Lai J., King T., Vanderah T.W., and Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 80 (2005) 319-324
64. Pasternak G.W. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological Sciences 22 (2001) 67-70
65. Perry S.J., and Lefkowitz R.J. Arresting developments in heptahelical receptor signaling and regulation. Trends in Cell Biology 12 (2002) 130-138
66. Price D.D., von der Gruen A., Miller J., Rafii A., and Price C. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist. Anesthesia & Analgesia 64 (1985) 801-806
67. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews 3 (2004) CD004847
68. Quirion R. Pain, nociception and spinal opioid receptors. Progress in Neuro-psychopharmacology & Biological Psychiatry 8 (1984) 571-579
69. Quirion R., Zajac J.M., Morgat J.L., and Roques B.P. Autoradiographic distribution of mu and delta opiate receptors in rat brain using highly selective ligands. Life Sciences 33 Suppl 1 (1983) 227-230
70. Raehal K.M., and Bohn L.M. Mu opioid receptor regulation and opiate responsiveness. AAPS Journal 7 (2005) E587-E591
71. Ross J.R., Riley J., Quigley C., and Welsh K.I. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist 11 (2006) 765-773
72. Ross J.R., Rutter D., Welsh K., Joel S.P., Goller K., Wells A.U., et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics Journal 5 (2005) 324-336
73. Saeki S., and Yaksh T.L. Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesthesia & Analgesia 77 (1993) 265-274
74. Sander T., Gscheidel N., Wendel B., Smolka M., Rommelspacher H., Schmidt L.G., and Hoche M.R. Human mu-opioid receptor variation and alcohol dependence. AlcoholismClinical & Experimental Research 22 (1998) 2108-2110
75. Shen K.F., and Crain S.M. Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors. Brain Research 525 (1990) 225-231
76. Sim-Selley L.J., Selley D.E., Vogt L.J., Childers S.R., and Martin T.J. Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. Journal of Neuroscience 20 (2000) 4555-4562
77. Sim L.J., Selley D.E., Dworkin S.I., and Childers S.R. Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. Journal of Neuroscience 16 (1996) 2684-2692
78. Sjogren P., Thunedborg L.P., Christrup L., Hansen S.H., and Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiologica Scandinavica 42 (1998) 1070-1075
79. Sosnowski M., and Yaksh T.L. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 73 (1990) 1141-1147
80. Tang J., Chou J., Iadarola M., Yang H.Y., and Costa E. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology 23 (1984) 715-718
81. Terman G.W., Jin W., Cheong Y.P., Lowe J., Caron M.G., Lefkowitz R.J., et al. G-Protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. British Journal of Pharmacology 141 (2004) 55-64
82. Terner J.M., Barrett A.C., Lomas L.M., Negus S.S., and Picker M.J. Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain 122 (2006) 90-101
83. Thomsen A.B., Becker N., and Eriksen J. Opioid rotation in chronic nonmalignant pain patients. A retrospective study. Acta Anaesthesiologica Scandinavica 43 (1999) 918-923
84. Town T., Abdullah L., Crawford F., Schinka J., Ordorica P.I., Francis E., Hughes P., Duara R., and Mullan M. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. American Journal of Medical Genetics 88 (1999) 458-461
85. Van Bockstaele E.J., Colago E.E., Cheng P., Moriwaki A., Uhl G.R., and Pickel V.M. Ultrastructural evidence for prominent distribution of the mu-opioid receptor at extrasynaptic sites on noradrenergic dendrites in the rat nucleus locus coeruleus. Journal of Neuroscience 16 (1996) 5037-5048
86. Vanderah T.W., Gardell L.R., Burgess S.E., Ibrahim M., Dogrul A., Zhong C.M., et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. Journal of Neuroscience 20 (2000) 7074-7079
87. Vanderah T.W., Suenaga N.M., Ossipov M.H., Malan Jr. T.P., Lai J., and Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. Journal of Neuroscience 21 (2001) 279-286
88. Vigano A., Fan D., and Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 67 (1996) 115-119
89. Wang H.Y., Friedman E., Olmstead M.C., and Burns L.H. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 135 (2005) 247-261
90. Watkins L.R., Kinscheck I.B., and Mayer D.J. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224 (1984) 395-396
91. White P.F. The changing role of nonopioid analgesic techniques in the management of postoperative pain. Anesthesia & Analgesia 101 5 Suppl (2005) S5-S22
92. Xu X.J., Wiesenfeld-Hallin Z., Hughes J., Horwell D.C., and Hokfelt T. CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat. British Journal of Pharmacology 105 (1992) 591-596
93. Yabaluri N., and Medzihradsky F. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling. Molecular Pharmacology 52 (1997) 896-902
94. Yoburn B.C., Gomes B.A., Rajashekara V., Patel C., and Patel M. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo. Synapse 47 (2003) 109-116